Skip to main content
. 2020 Sep 17;20:371. doi: 10.1186/s12886-020-01637-0

Table 2.

Treatment responder patients at month 3 and 6

DME responder patients Month 3
(n/N)
Month 6
(n/N)
Additional responder patients
(month 6 vs month 3)
Aflibercept (Eylea®) 93.48/190 130/190 36.52
Ranibizumab (Lucentis®) 82.34/176 103/176 20.66
Bevacizumab (Avastin®) 48.81/180 62/180 13.19